Capecitabine-induced hand-foot syndrome does not emerge in the complex regional pain syndrome-affected limb: A case report.
anhidrosis
breast cancer
capecitabine
complex regional pain syndrome
hand-foot syndrome
Journal
Molecular and clinical oncology
ISSN: 2049-9469
Titre abrégé: Mol Clin Oncol
Pays: England
ID NLM: 101613422
Informations de publication
Date de publication:
Dec 2021
Dec 2021
Historique:
received:
28
04
2021
accepted:
15
07
2021
entrez:
21
10
2021
pubmed:
22
10
2021
medline:
22
10
2021
Statut:
ppublish
Résumé
Hand-foot syndrome (HFS) is a frequent adverse effect of various anti-tumour drugs, such as capecitabine, that affects their dose-limiting toxicity. The mechanism of HFS remains unknown and there are currently no effective strategies to treat HFS, except for cessation. The current study presented a female case where one hand, affected by brachial plexus infiltration due to the subclavian lymph node metastasis of breast cancer, exhibited not only pain and partial motor paralysis but also anhidrosis, oedema and skin colour changes. The patient met the diagnostic criteria for complex regional pain syndrome (CRPS). After treatment with capecitabine, their anhidrosis hand completely prevented HFS. The other hand and both feet demonstrated typical symptoms of HFS, which improved consequent to capecitabine cessation. The CRPS-affected hand remained normal. Considering the limited presentation of HFS concomitant with anhidrosis, the exocrine release of condensed capecitabine through sweat glands might be a promising mechanism of HFS induction.
Identifiants
pubmed: 34671472
doi: 10.3892/mco.2021.2416
pii: MCO-15-6-02416
pmc: PMC8521386
doi:
Types de publication
Case Reports
Langues
eng
Pagination
254Informations de copyright
Copyright © 2020, Spandidos Publications.
Références
Pain. 2010 Aug;150(2):243-249
pubmed: 20451323
N Engl J Med. 2005 Jun 30;352(26):2696-704
pubmed: 15987918
Ann Oncol. 2012 May;23(5):1348-1353
pubmed: 21940785
Anticancer Res. 2009 Jun;29(6):2307-13
pubmed: 19528496
J Biomed Opt. 2016 Apr 30;21(4):47002
pubmed: 27117193
Arch Dermatol. 2011 Dec;147(12):1418-23
pubmed: 22184763
Clin Colorectal Cancer. 2006 Sep;6(3):219-23
pubmed: 17026792
Environ Toxicol Pharmacol. 2017 Jan;49:81-88
pubmed: 27951409
Clin J Pain. 1998 Mar;14(1):48-54
pubmed: 9535313
Cutan Ocul Toxicol. 2010 Jun;29(2):140-2
pubmed: 20298142
Support Care Cancer. 2014 Jun;22(6):1585-93
pubmed: 24463616
J Clin Pharmacol. 2004 Oct;44(10):1166-72
pubmed: 15342618
Oncology (Williston Park). 2002 Dec;16(12 Suppl No 14):31-7
pubmed: 12520638
Clin Colorectal Cancer. 2012 Mar;11(1):82-4
pubmed: 21764392
Ann Pharmacother. 2015 Oct;49(10):1120-4
pubmed: 26160973
J Am Acad Dermatol. 2014 Oct;71(4):787-94
pubmed: 24795111
Dermatologica. 1974;148(2):90-2
pubmed: 4276191
Intern Med. 2015;54(21):2779
pubmed: 26521911
Pain Pract. 2018 Mar;18(3):341-349
pubmed: 28691184